Reed Seward

For decades, randomized controlled trials, commonly known as RCTs, have represented the highest standard for evaluating new medicines and treatments. These studies use careful designs to compare treatment groups and control for factors that could influence the results. Because of their controlled design, RCTs have helped researchers determine whether medical interventions are safe and effective before they reach patients. However, as healthcare becomes more complex, many experts are recognizing that traditional trials may not answer every important question. Furthermore, real-world evidence has gained attention as a valuable complement to traditional clinical research. This type of evidence comes from information collected during everyday healthcare experiences, including patient records, insurance data, and treatment outcomes outside controlled study environments. Therefore, researchers can gain a broader understanding of how treatments perform across diverse populations in real-worl...

Clinical Trials Are Becoming More Flexible Adaptive trial designs are changing the way new drugs move through research . In the past, many clinical trials used a fixed plan. Researchers decided the study size, patient group , dose, and main goal before the trial began. Then they followed that plan until the end. That method can still be useful. Yet drug development is often uncertain. A treatment may work better in one group than another. A dose may be too low or too strong. Early data may show that a trial needs a smarter path. Adaptive trial designs give researchers a way to make planned changes while the study is still running. What Adaptive Trial Designs Do Adaptive trial designs allow a clinical trial to change based on study data. These changes are not random. They must be planned before the trial starts. The rules must be clear, fair, and approved. A study may use adaptive trial designs to change the sample size. It may stop a weak treatment arm. It may focus on a group of pati...

Clinical trial success often begins long before the first participant enrolls. One of the most critical decisions is selecting research sites that can recruit patients, adhere to study protocols, and deliver reliable data. Traditional site selection methods have relied heavily on historical performance and manual reviews, which can limit visibility into current site capabilities. Today, machine learning is transforming this process by analyzing vast amounts of information to uncover meaningful patterns and opportunities. Through intelligent site selection , sponsors can identify stronger research locations with greater confidence. Furthermore, machine learning helps reduce uncertainty, improve planning, and support faster study execution in an increasingly competitive clinical research environment. The Growing Complexity of Site Selection Clinical research has become more complex as studies involve larger datasets, stricter regulations, and broader patient populations. Therefore, selec...